<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:21:37Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10258437" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10258437</identifier>
        <datestamp>2023-06-13</datestamp>
        <setSpec>chest</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article" dtd-version="1.3">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Chest</journal-id>
              <journal-id journal-id-type="iso-abbrev">Chest</journal-id>
              <journal-title-group>
                <journal-title>Chest</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0012-3692</issn>
              <issn pub-type="epub">1931-3543</issn>
              <publisher>
                <publisher-name>American College of Chest Physicians</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10258437</article-id>
              <article-id pub-id-type="pmcid">PMC10258437</article-id>
              <article-id pub-id-type="pmc-uid">10258437</article-id>
              <article-id pub-id-type="pmid">36356657</article-id>
              <article-id pub-id-type="pii">S0012-3692(22)04053-3</article-id>
              <article-id pub-id-type="doi">10.1016/j.chest.2022.10.037</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Diffuse Lung Disease: Original Research</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Efzofitimod for the Treatment of Pulmonary Sarcoidosis</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" id="au1">
                  <name>
                    <surname>Culver</surname>
                    <given-names>Daniel A.</given-names>
                  </name>
                  <degrees>DO</degrees>
                  <email>culverd@ccf.org</email>
                  <xref rid="aff1" ref-type="aff">a</xref>
                  <xref rid="cor1" ref-type="corresp">∗</xref>
                </contrib>
                <contrib contrib-type="author" id="au2">
                  <name>
                    <surname>Aryal</surname>
                    <given-names>Shambhu</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff3" ref-type="aff">b</xref>
                </contrib>
                <contrib contrib-type="author" id="au3">
                  <name>
                    <surname>Barney</surname>
                    <given-names>Joseph</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff4" ref-type="aff">c</xref>
                </contrib>
                <contrib contrib-type="author" id="au4">
                  <name>
                    <surname>Hsia</surname>
                    <given-names>Connie C.W.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff5" ref-type="aff">d</xref>
                </contrib>
                <contrib contrib-type="author" id="au5">
                  <name>
                    <surname>James</surname>
                    <given-names>W. Ennis</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff6" ref-type="aff">e</xref>
                </contrib>
                <contrib contrib-type="author" id="au6">
                  <name>
                    <surname>Maier</surname>
                    <given-names>Lisa A.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff7" ref-type="aff">f</xref>
                  <xref rid="aff8" ref-type="aff">g</xref>
                </contrib>
                <contrib contrib-type="author" id="au7">
                  <name>
                    <surname>Marts</surname>
                    <given-names>Lucian T.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff9" ref-type="aff">h</xref>
                </contrib>
                <contrib contrib-type="author" id="au8">
                  <name>
                    <surname>Obi</surname>
                    <given-names>Ogugua Ndili</given-names>
                  </name>
                  <degrees>MD, MPH</degrees>
                  <xref rid="aff10" ref-type="aff">i</xref>
                </contrib>
                <contrib contrib-type="author" id="au9">
                  <name>
                    <surname>Sporn</surname>
                    <given-names>Peter H.S.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff11" ref-type="aff">j</xref>
                </contrib>
                <contrib contrib-type="author" id="au10">
                  <name>
                    <surname>Sweiss</surname>
                    <given-names>Nadera J.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff12" ref-type="aff">k</xref>
                  <xref rid="aff13" ref-type="aff">l</xref>
                </contrib>
                <contrib contrib-type="author" id="au11">
                  <name>
                    <surname>Shukla</surname>
                    <given-names>Sanjay</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff14" ref-type="aff">m</xref>
                </contrib>
                <contrib contrib-type="author" id="au12">
                  <name>
                    <surname>Kinnersley</surname>
                    <given-names>Nelson</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="aff15" ref-type="aff">n</xref>
                </contrib>
                <contrib contrib-type="author" id="au13">
                  <name>
                    <surname>Walker</surname>
                    <given-names>Gennyne</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="aff14" ref-type="aff">m</xref>
                </contrib>
                <contrib contrib-type="author" id="au14">
                  <name>
                    <surname>Baughman</surname>
                    <given-names>Robert</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff2" ref-type="aff">o</xref>
                </contrib>
                <aff id="aff1"><label>a</label>Cleveland Clinic, Cleveland, OH</aff>
                <aff id="aff3"><label>b</label>Advanced Lung Disease and Lung Transplant Program, Inova Fairfax Hospital, Falls Church, VA</aff>
                <aff id="aff4"><label>c</label>Department of Pulmonary and Critical Care Medicine, University of Alabama, Birmingham, AL</aff>
                <aff id="aff5"><label>d</label>Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX</aff>
                <aff id="aff6"><label>e</label>Susan Pearlstine Sarcoidosis Center of Excellence, Pulmonary and Critical Care Medicine, Medical University of South Carolina, Charleston, SC</aff>
                <aff id="aff7"><label>f</label>Division of Environmental and Occupational Health Sciences, National Jewish Health</aff>
                <aff id="aff8"><label>g</label>Division of Pulmonary Sciences and Critical Care, Department of Medicine, School of Medicine, University of Colorado, Denver, CO</aff>
                <aff id="aff9"><label>h</label>Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, Department of Medicine, Emory University School of Medicine, Atlanta, GA</aff>
                <aff id="aff10"><label>i</label>Division of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, Brody School of Medicine East Carolina University, Greenville, NC</aff>
                <aff id="aff11"><label>j</label>Division of Pulmonary and Critical Care Medicine, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL</aff>
                <aff id="aff12"><label>k</label>Division of Rheumatology and Medical Director of the Arthritis Clinic, Chicago, IL</aff>
                <aff id="aff13"><label>l</label>Bernie Mac Sarcoidosis Translational Advanced Research Center, University of Illinois College of Medicine, Chicago, IL</aff>
                <aff id="aff14"><label>m</label>aTyr Pharma, Inc., San Diego, CA</aff>
                <aff id="aff15"><label>n</label>Octa Consulting Services, Ltd., Harpenden, England</aff>
                <aff id="aff2"><label>o</label>Department of Medicine, University of Cincinnati Medical Center, Cincinnati, OH</aff>
              </contrib-group>
              <author-notes>
                <corresp id="cor1"><label>∗</label><bold>CORRESPONDENCE TO:</bold> Daniel A. Culver, DO <email>culverd@ccf.org</email></corresp>
              </author-notes>
              <pub-date pub-type="pmc-release">
                <day>08</day>
                <month>11</month>
                <year>2022</year>
              </pub-date>
              <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
              <pub-date pub-type="ppub">
                <month>4</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>08</day>
                <month>11</month>
                <year>2022</year>
              </pub-date>
              <volume>163</volume>
              <issue>4</issue>
              <fpage>881</fpage>
              <lpage>890</lpage>
              <permissions>
                <copyright-statement>© 2022 The Authors</copyright-statement>
                <copyright-year>2022</copyright-year>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p>
                </license>
              </permissions>
              <abstract id="abs0010">
                <sec>
                  <title>Background</title>
                  <p>Pulmonary sarcoidosis is characterized by the accumulation of immune cells that form granulomas affecting the lungs. Efzofitimod (ATYR1923), a novel immunomodulator, selectively binds neuropilin 2, which is upregulated on immune cells in response to lung inflammation.</p>
                </sec>
                <sec>
                  <title>Research Question</title>
                  <p>What is the tolerability, safety, and effect on outcomes of efzofitimod in pulmonary sarcoidosis?</p>
                </sec>
                <sec>
                  <title>Study Design And Methods</title>
                  <p>In this randomized, double-blind, placebo-controlled study evaluating multiple ascending doses of efzofitimod administered intravenously every 4 weeks for 24 weeks, randomized patients (2:1) underwent a steroid taper to 5 mg/d by week 8 or &lt; 5 mg/d after week 16. The primary end point was the incidence of adverse events (AEs); secondary end points included steroid reduction, change in lung function, and patient-reported outcomes on health-related quality-of-life scales.</p>
                </sec>
                <sec>
                  <title>Results</title>
                  <p>Thirty-seven patients received at least one dose of study medication. Efzofitimod was well tolerated at all doses, with no new or unexpected AEs and no dose-dependent AE incidence. Average daily steroid doses through end of study were 6.8 mg, 6.5 mg, and 5.6 mg for the 1 mg/kg, 3 mg/kg, and 5 mg/kg groups compared with 7.2 mg for placebo, resulting in a baseline-adjusted relative steroid reduction of 5%, 9%, and 22%, respectively. Clinically meaningful improvements were achieved across several patient-reported outcomes, several of which reached statistical significance in the 5 mg/kg dose arm. A dose-dependent but nonsignificant trend toward improved lung function also was observed for 3 and 5 mg/kg.</p>
                </sec>
                <sec>
                  <title>Interpretation</title>
                  <p>Efzofitimod was safe and well tolerated and was associated with dose-dependent improvements of several clinically relevant end points compared with placebo. The results of this study support further evaluation of efzofitimod in pulmonary sarcoidosis.</p>
                </sec>
                <sec>
                  <title>Trial Registry</title>
                  <p>ClinicalTrials.gov; No.: NCT03824392; URL: <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov" id="intref0010">www.clinicaltrials.gov</ext-link></p>
                </sec>
              </abstract>
              <abstract abstract-type="graphical" id="abs0015a">
                <title>Graphical Abstract</title>
                <fig id="undfig1" position="anchor">
                  <graphic xlink:href="fx1"/>
                </fig>
              </abstract>
              <kwd-group id="kwrds0010">
                <title>Key Words</title>
                <kwd>ATYR1923</kwd>
                <kwd>corticosteroids</kwd>
                <kwd>efzofitimod</kwd>
                <kwd>fatigue assessment scale</kwd>
                <kwd>immunomodulator</kwd>
                <kwd>lung function</kwd>
                <kwd>neuropilin 2</kwd>
                <kwd>pulmonary sarcoidosis</kwd>
                <kwd>quality of life</kwd>
                <kwd>steroid taper</kwd>
              </kwd-group>
            </article-meta>
            <def-list>
              <title>Abbreviations</title>
              <def-item>
                <term id="kwrd0065">AE</term>
                <def>
                  <p>adverse event</p>
                </def>
              </def-item>
              <def-item>
                <term id="kwrd0075">D<sc>lco</sc></term>
                <def>
                  <p>diffusing capacity of the lungs for carbon monoxide</p>
                </def>
              </def-item>
              <def-item>
                <term id="kwrd0085">efzofitimod</term>
                <def>
                  <p>ATYR1923</p>
                </def>
              </def-item>
              <def-item>
                <term id="kwrd0095">FAS</term>
                <def>
                  <p>Fatigue Assessment Scale</p>
                </def>
              </def-item>
              <def-item>
                <term id="kwrd0105">GH</term>
                <def>
                  <p>general health</p>
                </def>
              </def-item>
              <def-item>
                <term id="kwrd0115">IRR</term>
                <def>
                  <p>infusion-related reaction</p>
                </def>
              </def-item>
              <def-item>
                <term id="kwrd0125">KSQ</term>
                <def>
                  <p>King’s Sarcoidosis Questionnaire</p>
                </def>
              </def-item>
              <def-item>
                <term id="kwrd0135">MCID</term>
                <def>
                  <p>minimal clinically important difference</p>
                </def>
              </def-item>
              <def-item>
                <term id="kwrd0145">PRO</term>
                <def>
                  <p>patient-reported outcome</p>
                </def>
              </def-item>
              <def-item>
                <term id="kwrd0155">QOL</term>
                <def>
                  <p>quality of life</p>
                </def>
              </def-item>
              <def-item>
                <term id="kwrd0165">SAT</term>
                <def>
                  <p>Sarcoidosis Assessment Tool</p>
                </def>
              </def-item>
              <def-item>
                <term id="kwrd0175">TEAE</term>
                <def>
                  <p>treatment-emergent adverse event</p>
                </def>
              </def-item>
            </def-list>
          </front>
          <body>
            <p id="p0010">
              <boxed-text id="dtbox1">
                <caption>
                  <title>Take-home Points</title>
                </caption>
                <p id="p0015"><bold>Research</bold><bold>Q</bold><bold>uestion:</bold> What is the tolerability of efzofitimod for pulmonary sarcoidosis, and can we discern any evidence of clinical efficacy to support a larger trial?</p>
                <p id="p0020"><bold>Results</bold>: No differences were found in adverse effects or tolerability between participants randomized to efzofitimod or placebo. Patient-reported outcomes improved in the higher-dose arms and positive trends for other end points were found.</p>
                <p id="p0025"><bold>Interpretation:</bold> Efzofitimod may be useful for pulmonary sarcoidosis. Larger studies are needed to confirm and extend these findings.</p>
              </boxed-text>
            </p>
            <p id="p0030">Sarcoidosis is a multisystem, granulomatous disorder that most commonly affects the lungs.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> Patients often demonstrate organ-specific symptoms such as dyspnea and cough, but also show a range of other disabling nonspecific symptoms (eg, fatigue) that have a major impact on quality of life (QOL). For patients with pulmonary sarcoidosis, the goal of treatment is to reduce the risk of death or permanent disability (danger) or to improve the patient’s QOL,<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> while secondarily managing the inflammation that may lead to pulmonary fibrosis and irreversible loss of lung function.<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref><sup>,</sup><xref rid="bib4" ref-type="bibr"><sup>4</sup></xref> The consensus standard of care includes oral corticosteroids that act mainly by suppressing inflammatory genes.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref><sup>,</sup><xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> Although corticosteroid therapy has been shown to stabilize or improve the disease, long-term corticosteroid use is associated with significant side effects, including substantial weight gain, development of insulin resistance, risk of infection,<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref> and impaired QOL.<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref> Alternatives, such as immunosuppressive and cytotoxic agents (eg, methotrexate), can be used; however, these therapies also have significant side effects and toxicities.<xref rid="bib8" ref-type="bibr"><sup>8</sup></xref> Hence, a need exists to find new and effective treatments for pulmonary sarcoidosis with fewer side effects and a positive impact on QOL.</p>
            <p id="p0035">Efzofitimod (ATYR1923) is a novel IV biological immunomodulator composed of a splice variant of histidyl-tRNA synthetase<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref><sup>,</sup><xref rid="bib10" ref-type="bibr"><sup>10</sup></xref> that encodes the immunomodulatory domain that binds to the neuropilin 2 receptor protein.<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref> Neuropilin 2 is a pleiotropic receptor<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref> that is upregulated on the surface of activated immune cells responsible for inflammation and granuloma formation in the lungs of patients with pulmonary sarcoidosis.<xref rid="bib13" ref-type="bibr"><sup>13</sup></xref> Preclinical studies have shown that efzofitimod regulates immune responses<xref rid="bib14" ref-type="bibr">14</xref>, <xref rid="bib15" ref-type="bibr">15</xref>, <xref rid="bib16" ref-type="bibr">16</xref> and significantly reduces lung fibrosis and inflammation.<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref><sup>,</sup><xref rid="bib18" ref-type="bibr"><sup>18</sup></xref> Thus, efzofitimod may leverage a naturally occurring human immunomodulatory function to control or balance the human immune system therapeutically.</p>
            <p id="p0040">In healthy volunteers, single doses of efzofitimod (0.03-5 mg/kg) are well tolerated, with no significant safety concerns.<xref rid="bib19" ref-type="bibr"><sup>19</sup></xref> Efzofitimod pharmacokinetics are dose proportional over the range of 0.03 to 5.0 mg/kg, with a mean half-life ranging from 167 to 242 h (7-10 days), supporting once every 4 weeks dosing.<xref rid="bib19" ref-type="bibr"><sup>19</sup></xref> Herein, we present the primary clinical data from the first investigation of efzofitimod in patients with pulmonary sarcoidosis designed to evaluate the safety, tolerability, and preliminary efficacy in this patient population.</p>
            <sec id="sec1">
              <title>Study Design and Methods</title>
              <sec id="sec1.1">
                <title>Trial Design and Procedures</title>
                <p id="p0045">Patients were 18 to 75 years of age, had a diagnosis of pulmonary sarcoidosis for ≥ 6 months according to the 1999 American Thoracic Society standards,<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref> and showed evidence of parenchymal involvement. The full inclusion and exclusion criteria are provided in <xref rid="appsec1" ref-type="sec">e-Appendix 1</xref>.</p>
                <p id="p0050">This was a randomized, double-blind, placebo-controlled multiple ascending dose study with three sequential dose cohorts with a 2:1 randomization (efzofitimod to placebo) in each cohort; the planned study size was 36 patients (<ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov" id="intref0015">ClinicalTrials.gov</ext-link> Identifier: NCT03824392). Patients receiving placebo from each of the three cohorts were pooled when comparing safety and efficacy between placebo and efzofitimod. The treatment period consisted of six IV administrations of study drug (efzofitimod or placebo) once every 4 weeks for a total of 20 weeks (at day 1 and weeks 4, 8, 12, 16, and 20), with the final study assessments conducted at week 24.</p>
                <p id="p0055">Safety and tolerability assessments consisted of evaluation of treatment-emergent adverse events (TEAEs), physical examinations, vital signs and temperature, 12-lead ECGs, pulse oximetry, weight, immunogenicity, and clinical laboratory tests. Assessment of daily corticosteroid dose over the study period (day 1-week 24) and the number of patients who achieved the targeted tapered dose of prednisone 5 mg/day (or equivalent) through week 24 also were recorded. Pulmonary function tests including the FVC % predicted and diffusing capacity of the lungs for carbon monoxide (D<sc>lco</sc>) % predicted were also performed. Patient-reported QOL was assessed by the Sarcoidosis Assessment Tool (SAT), the King’s Sarcoidosis Questionnaire (KSQ), the Leicester Cough Questionnaire, the Fatigue Assessment Scale (FAS), and the Self-Administered Computerized Baseline and Transitional Dyspnea Indices. The schedule of assessments is presented in <xref rid="appsec1" ref-type="sec">e-Table 1</xref>.</p>
                <p id="p0060">Starting on day 15, patients began a taper (reduction) of corticosteroid from the starting dose of 10 to 25 mg/d of prednisone (or equivalent) to a target dose of 5 mg/d, which was to be completed on or before day 50. The corticosteroid dose was to be tapered every 1 to 2 weeks, depending on the starting dose, with smaller incremental titrations allowed per the investigator’s judgment, as long as the patient reached the goal dose by day 50. Patients were maintained at the target corticosteroid dose of 5 mg/d (or equivalent) through week 24. Optional titrations in the corticosteroid dose &lt; 5 mg/d could occur after week 16 if the investigator determined further titration to be feasible. Patients who demonstrated acute worsening of sarcoidosis symptoms or who were unable to tolerate the taper were allowed to receive rescue treatment with higher corticosteroid doses per the site investigators’ clinical judgement; on resolution of symptoms, the taper could be reattempted per the investigators’ judgment.</p>
              </sec>
              <sec id="sec1.2">
                <title>Outcomes and Statistical Analysis</title>
                <p id="p0065">The primary end point was to evaluate the safety and tolerability of efzofitimod vs placebo in patients with pulmonary sarcoidosis. Adverse events (AEs) were recorded from the date of informed consent and coded using the Medical Dictionary for Regulatory Activities version 24.0. TEAEs were defined as any AE or worsening of an existing condition after initiation of the study drug through 30 days after the last study. The intensity of each AE was rated by the masked investigator using the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. Please refer to <xref rid="appsec1" ref-type="sec">e-Appendix 1</xref> for grading of AEs. The TEAEs were summarized by frequency of occurrence, number of patients experiencing the event, relationship to study medication, intensity, and seriousness. Patients were monitored closely during study drug infusions, and any AEs that occurred during or within 24 h after study drug administration were captured as infusion-related reactions (IRRs).</p>
                <p id="p0070">For the secondary outcome of potential corticosteroid-sparing effect of efzofitimod, the analysis included the time-adjusted area under the receiver operating characteristic curve from baseline to week 24 for each patient and a corresponding area under the receiver operating characteristic curve for the posttaper period (day 51 through end of study). The time-adjusted area under the receiver operating characteristic curve approximates the average daily corticosteroid dose per patient over the respective period. The development of antidrug antibody and Jo-1 antibodies (antibodies that recognize histidyl-tRNA synthetase) was used to summarize immunogenicity.</p>
                <p id="p0075">Exploratory outcomes evaluated the change from baseline in lung function through week 24. The change in PRO scores from baseline to week 24 also were assessed as follows: SAT, sarcoidosis-specific patient-reported outcomes of impact of disease and response to therapy<xref rid="bib32" ref-type="bibr"><sup>21</sup></xref>; KSQ, 29-item questionnaire related to general health (GH) and lung (range, 1-100; higher numbers indicating better health<xref rid="bib21" ref-type="bibr"><sup>22</sup></xref>); Leicester Cough Questionnaire, 19-item self-complete QOL measure of chronic cough (range, 3-21; higher numbers indicating better QOL<xref rid="bib22" ref-type="bibr"><sup>23</sup></xref>); FAS, 10 fatigue-related questions (range, 10-50; scores of ≥ 22 are considered to represent substantial fatigue<xref rid="bib23" ref-type="bibr"><sup>24</sup></xref>); Self-Administered Computerized Baseline and Transitional Dyspnea Indices, graded assessments of changes in the severity of dyspnea at baseline and at subsequent visits (range, 0-12; the lower the score is the worse the severity of dyspnea<xref rid="bib24" ref-type="bibr"><sup>25</sup></xref>).</p>
                <p id="p0080">The primary analysis population (safety set) comprised all patients who received any amount of study drug and was based on the actual treatment received. The primary efficacy analysis was the modified intention-to-treat population, defined as all randomized patients who received at least one administration of study drug.</p>
                <p id="p0085">Statistical analyses were performed in an exploratory manner to reflect the phase 1/2 nature of the study. Continuous variables were summarized using descriptive statistics (number, mean ± SD, and median [interquartile range]). Categorical variables were summarized with the number and percentage of patients within each classification. Any calculated <italic>P</italic> values for exploratory variables were analyzed using either the analysis of covariance or a mixed model for repeated measures with the results presented as the difference between active groups and placebo in the least squares mean change.</p>
              </sec>
            </sec>
            <sec id="sec2">
              <title>Results</title>
              <sec id="sec2.1">
                <title>Baseline Characteristics and Patient Disposition</title>
                <p id="p0090">A total of 37 patients were randomized and received at least one dose of study drug: 12 received placebo and eight, eight, and nine patients received the 1 mg/kg, 3 mg/kg, and 5 mg/kg efzofitimod doses, respectively. Nine patients (24%) prematurely discontinued treatment, six because of COVID-19-related restrictions (eg, operational feasibility and site closures), two because of AEs, and one because of investigator decision. Twenty-eight patients (76%) completed the study (<xref rid="fig1" ref-type="fig">Fig 1</xref>).<fig id="fig1"><label>Figure 1</label><caption><p>Flow diagram showing patient disposition (Modified Intention-to-Treat Population). <sup>a</sup>Site closures related to the COVID-19 pandemic. AE = adverse event.</p></caption><graphic xlink:href="gr1"/></fig></p>
                <p id="p0095">Baseline demographic characteristics generally were well balanced across the treatment groups. The mean ± SD age was 52.4 ± 10.1 years, with 54% women, 62% White, and 38% Black patients. Baseline disease characteristics, including pulmonary function, were similar across treatment groups. Background corticosteroid use generally was comparable across treatment groups; of note, more patients in the placebo group were receiving concomitant immunomodulators compared with the efzofitimod treatment groups. Nearly all patients (36 [97%]) were receiving prednisone (one received methylprednisolone), with a mean ± SD daily steroid dose of 13.2 ± 4.4 mg/d, and 22 patients (59.5%) receiving 10 to &lt; 15 mg/d of prednisone equivalent dose. Demographics and disposition by treatment group are presented in <xref rid="tbl1" ref-type="table">Table 1</xref>.<table-wrap position="float" id="tbl1"><label>Table 1</label><caption><p>Baseline Demographics, Disease Characteristics, and Corticosteroid and Immunomodulator Use (Modified Intention-to-Treat Population<xref rid="tbl1fna" ref-type="table-fn">a</xref>)</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Variable</th><th rowspan="2">Placebo (n = 12)</th><th colspan="3">Efzofitimod<hr/></th><th rowspan="2">All (n = 37)</th></tr><tr><th>1 mg/kg (n = 8)</th><th>3 mg/kg (n = 8)</th><th>5 mg/kg (n = 9)</th></tr></thead><tbody><tr><td>Age, y</td><td align="center">52.5 ± 10.2</td><td align="center">54.5 ± 11.3</td><td align="center">51.8 ± 11.4</td><td align="center">50.8 ± 9.8</td><td align="center">52.4 ± 10.1</td></tr><tr><td>Sex, female</td><td align="center">7 (58.3)</td><td align="center">4 (50)</td><td align="center">4 (50)</td><td align="center">5 (55.6)</td><td align="center">20 (54.1)</td></tr><tr><td>Race</td><td/><td/><td/><td/><td/></tr><tr><td> White</td><td align="center">9 (75)</td><td align="center">5 (62.5)</td><td align="center">6 (75)</td><td align="center">3 (33.3)</td><td align="center">23 (62.2)</td></tr><tr><td> Black</td><td align="center">3 (25)</td><td align="center">3 (37.5)</td><td align="center">2 (25)</td><td align="center">6 (66.7)</td><td align="center">14 (37.8)</td></tr><tr><td>Duration of disease, y</td><td/><td/><td/><td/><td/></tr><tr><td> Median</td><td align="center">2.9</td><td align="center">5.3</td><td align="center">4.3</td><td align="center">2.9</td><td align="center">4.2</td></tr><tr><td> Range</td><td align="center">0.5, 10.2</td><td align="center">1.5, 19.6</td><td align="center">0.6, 15.0</td><td align="center">0.5, 28.0</td><td align="center">0.5, 28.0</td></tr><tr><td>Baseline BDI total score</td><td align="center">4.8 ± 2</td><td align="center">4.3 ± 1.8</td><td align="center">7.6 ± 2.9</td><td align="center">6.3 ± 2.5</td><td align="center">5.65 ± 2.54</td></tr><tr><td>Baseline lung function</td><td/><td/><td/><td/><td/></tr><tr><td> mMRC dyspnea scale score</td><td/><td/><td/><td/><td/></tr><tr><td> 1-2</td><td align="center">8 (66.7)</td><td align="center">3 (37.5)</td><td align="center">8 (100)</td><td align="center">5 (55.6)</td><td align="center">24 (64.9)</td></tr><tr><td> 3-4</td><td align="center">4 (33.3)</td><td align="center">5 (62.5)</td><td align="center">0</td><td align="center">4 (44.4)</td><td align="center">13 (35.1)</td></tr><tr><td> FEV<sub>1</sub>, % predicted</td><td align="center">68.3 ± 20.1</td><td align="center">60.4 ± 10.2</td><td align="center">77.6 ± 11.1</td><td align="center">77.3 ± 19.5</td><td align="center">70.8 ± 17.3</td></tr><tr><td> FVC, % predicted</td><td align="center">77.3 ± 11.5</td><td align="center">68.3 ± 9.7</td><td align="center">83.8 ± 7.3</td><td align="center">83.8 ± 16.6</td><td align="center">78.3 ± 12.9</td></tr><tr><td> FEV<sub>1</sub> to FVC ratio</td><td align="center">0.7 ± 0.15</td><td align="center">0.7 ± 0.08</td><td align="center">0.73 ± 0.08</td><td align="center">0.72 ± 0.1</td><td align="center">0.715 ± 0.11</td></tr><tr><td> D<sc>lco,</sc> % predicted</td><td align="center">61.7 ± 19.7</td><td align="center">61.9 ± 21.4</td><td align="center">75.5 ± 19.9</td><td align="center">54.5 ± 14.1</td><td align="center">63.8 ± 19.8</td></tr><tr><td>Baseline steroid use</td><td/><td/><td/><td/><td/></tr><tr><td> Prednisone equivalent dose, mg/d<xref rid="tbl1fnb" ref-type="table-fn">b</xref></td><td align="center">13.3 ± 4.4</td><td align="center">11.3 ± 3.5</td><td align="center">14.4 ± 6.2</td><td align="center">13.9 ± 3.3</td><td align="center">13.2 ± 4.4</td></tr><tr><td> 10 to &lt; 15</td><td align="center">7 (58.3)</td><td align="center">7 (87.5)</td><td align="center">5 (62.5)</td><td align="center">3 (33.3)</td><td align="center">22 (59.5)</td></tr><tr><td> 15 to &lt; 20</td><td align="center">2 (16.7)</td><td align="center">0</td><td align="center">0</td><td align="center">5 (55.6)</td><td align="center">7 (18.9)</td></tr><tr><td> ≥ 20</td><td align="center">3 (25)</td><td align="center">1 (12.5)</td><td align="center">3 (37.5)</td><td align="center">1 (11.1)</td><td align="center">8 (21.6)</td></tr><tr><td>Baseline immunomodulator use</td><td/><td/><td/><td/><td/></tr><tr><td> Methotrexate</td><td align="center">4 (33.3)</td><td align="center">2 (25)</td><td align="center">0</td><td align="center">3 (33.3)</td><td align="center">9 (24.3)</td></tr><tr><td> Azathioprine</td><td align="center">2 (16.7)</td><td align="center">0</td><td align="center">0</td><td align="center">1 (11.1)</td><td align="center">3 (8.1)</td></tr><tr><td> Hydroxychloroquine</td><td align="center">0</td><td align="center">1 (12.5)</td><td align="center">0</td><td align="center">0</td><td align="center">1 (2.7)</td></tr><tr><td> Leflunomide</td><td align="center">0</td><td align="center">0</td><td align="center">1 (12.5)</td><td align="center">0</td><td align="center">1 (2.7)</td></tr><tr><td> None</td><td align="center">6 (50)</td><td align="center">5 (62.5)</td><td align="center">7 (87.5)</td><td align="center">5 (55.6)</td><td align="center">23 (62.2)</td></tr></tbody></table><table-wrap-foot><fn><p>Data are presented as No. (%) or mean ± SD, unless otherwise indicated. Baseline measurements were defined as the last measurement assessed on or before the first dose date. If multiple measures were obtained on day 1 (eg, vital signs, 12-lead ECG), the last measurement before the first dose was used as baseline. BDI = baseline dyspnea index;D<sc>lco</sc> = diffusing capacity of lungs for carbon monoxide; mMRC = modified Medical Research Council.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fna"><label>a</label><p id="ntpara0015">All randomized patients who received at least one administration of study drug.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fnb"><label>b</label><p id="ntpara0020">All steroids were converted to prednisone dose equivalent.</p></fn></table-wrap-foot></table-wrap></p>
              </sec>
              <sec id="sec2.2">
                <title>Safety and Tolerability</title>
                <p id="p0100">No deaths or drug-related serious AEs were observed in the study. Overall, the proportion of patients with an AE was similar between the placebo and efzofitimod treatment groups, with no relationship between AE frequency and increased efzofitimod dose (<xref rid="tbl2" ref-type="table">Table 2</xref>). AEs within the respiratory system disorders system organ class were most common and included cough, wheezing, dyspnea, and upper respiratory tract infection (<xref rid="tbl2" ref-type="table">Table 2</xref>). These events were not dose dependent, tended to be mild in severity, and did not limit treatment duration. The high incidence of respiratory events across all treatment groups is expected in this patient population and aligns with the underlying disease.<table-wrap position="float" id="tbl2"><label>Table 2</label><caption><p>TEAEs &gt; 15% and Their Relationship to Treatment (Safety Set)</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Preferred Term All Causality</th><th rowspan="2">Placebo (n = 12)</th><th colspan="3">Efzofitimod<hr/></th></tr><tr><th>1 mg/kg (n = 8)</th><th>3 mg/kg (n = 8)</th><th>5 mg/kg (n = 9)</th></tr></thead><tbody><tr><td>Any TEAE</td><td align="center">10 (83.3)</td><td align="center">8 (100)</td><td align="center">7 (87.5)</td><td align="center">8 (88.9)</td></tr><tr><td> Cough</td><td align="center">1 (8.3)</td><td align="center">4 (50)</td><td align="center">2 (25)</td><td align="center">1 (11.1)</td></tr><tr><td> Fatigue</td><td align="center">0</td><td align="center">2 (25)</td><td align="center">1 (12.5)</td><td align="center">4 (44.4)</td></tr><tr><td> Wheezing</td><td align="center">0</td><td align="center">4 (50)</td><td align="center">0</td><td align="center">1 (11.1)</td></tr><tr><td> AST increased</td><td align="center">2 (16.7)</td><td align="center">0</td><td align="center">0</td><td align="center">0</td></tr><tr><td> Dizziness</td><td align="center">1 (8.3)</td><td align="center">1 (12.5)</td><td align="center">1 (12.5)</td><td align="center">2 (22.2)</td></tr><tr><td> Dyspnea</td><td align="center">0</td><td align="center">0</td><td align="center">2 (25)</td><td align="center">0</td></tr><tr><td> Arthralgia</td><td align="center">0</td><td align="center">1 (12.5)</td><td align="center">2 (25)</td><td align="center">0</td></tr><tr><td> Headache</td><td align="center">1 (8.3)</td><td align="center">0</td><td align="center">2 (25)</td><td align="center">1 (11.1)</td></tr><tr><td> Upper respiratory tract infection</td><td align="center">1 (8.3)</td><td align="center">1 (12.5)</td><td align="center">2 (25)</td><td align="center">0</td></tr><tr><td> Back pain</td><td align="center">0</td><td align="center">0</td><td align="center">2 (25)</td><td align="center">0</td></tr></tbody></table><table-wrap-foot><fn><p>Data are presented as No. (%). AST = aspartate aminotransferase; TEAE = treatment-emergent adverse event.</p></fn></table-wrap-foot></table-wrap></p>
                <p id="p0105">During the treatment period, four patients (33%) in the placebo group and four patients (16%) receiving efzofitimod experienced Grade 3 TEAEs. For placebo-treated patients, these events included urticaria, streptococcal sepsis, bradycardia, and worsening of pulmonary sarcoidosis. The relationship between sarcoidosis and study drug was designated as unlikely related, whereas urticaria was considered related to the study drug. One patient in the placebo arm experienced two Grade 3 AEs (bradycardia and worsening pulmonary sarcoidosis), which were considered unlikely to be related to the study drug. In efzofitimod-treated patients, two events occurred at 1 mg/kg (acute cholecystitis and depression) and two events occurred at 5 mg/kg (toothache and myalgia). None of the Grade 3 events reported with efzofitimod were considered possibly related or related. Serious TEAEs were reported in one patients (8.3%) who received placebo and one patient (4%) who received efzofitimod: streptococcal sepsis (placebo) and acute cholecystitis (1 mg/kg efzofitimod).</p>
                <p id="p0110">Two patients discontinued study treatment because of an AE, both of which were assessed as related to the study drug: one patient in the placebo group because of urticaria and one patient in the 1 mg/kg efzofitimod group because of alopecia. One additional patient in the 1 mg/kg efzofitimod group experienced an acute exacerbation of pulmonary sarcoidosis that was considered unrelated to study drug, but resulted in treatment discontinuation based on investigator discretion. Overall, the incidence of patients reporting IRRs was low, with only one patient in the 3 mg/kg efzofitimod group experiencing mild to moderate IRRs on three separate occasions that were considered by the investigator to be related to study drug, but did not require interruption of the infusion. No patients received efzofitimod who showed positive results for antiefzofitimod or antihistidyl-tRNA synthetase antibodies (eg, Jo-1), and no apparent trends were seen within or across treatment groups for vital signs, ECG findings, or blood oxygen saturation levels.</p>
              </sec>
              <sec id="sec2.3">
                <title>Corticosteroid Use, Lung Function, and QOL</title>
                <p id="p0115">The average daily dose of corticosteroid at baseline was comparable across treatment arms. All efzofitimod groups showed a lower corticosteroid use through week 24 compared with the placebo group. These reductions seemed to be dose dependent, with the largest percent reduction observed in the 5 mg/kg treatment group, with a 58% decrease from baseline (<xref rid="tbl3" ref-type="table">Table 3</xref>) compared with a 46% decrease in placebo, a difference of 12%. Average daily steroid doses through end of study were 6.8 mg, 6.5 mg, and 5.6 mg for the 1 mg/kg, 3 mg/kg, and 5 mg/kg groups, respectively, compared with 7.2 mg for the placebo group, resulting in a baseline-adjusted relative steroid reduction of 5%, 9%, and 22%, respectively. A comparison of adjusted means between placebo and efzofitimod revealed that the highest two efzofitimod treatment groups showed a larger, although statistically nonsignificant, percent decrease from baseline in overall corticosteroid use during the study (–2% for 3 mg/kg and –12% for 5 mg/kg) compared with placebo. Supporting these dose-related trends in corticosteroid reduction, three patients (33%) treated at the highest dose (5 mg/kg) were able to taper off corticosteroid completely and maintain this through the end of the study.<table-wrap position="float" id="tbl3"><label>Table 3</label><caption><p>Corticosteroid<xref rid="tbl3fna" ref-type="table-fn">a</xref> Burden (Modified Intention-to-Treat Population)</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Parameter</th><th rowspan="2">Placebo (n = 12)</th><th colspan="3">Efzofitimod<hr/></th></tr><tr><th>1 mg/kg (n = 8)</th><th>3 mg/kg (n = 8)</th><th>5 mg/kg (n = 9)</th></tr></thead><tbody><tr><td>Baseline prednisone equivalent dose, mg/d</td><td align="center">13.3 ± 4.4</td><td align="center">11.3 ± 3.5</td><td align="center">14.4 ± 6.2</td><td align="center">13.9 ± 3.3</td></tr><tr><td>Average daily dose, mg<xref rid="tbl3fnb" ref-type="table-fn">b</xref></td><td align="center">7.2</td><td align="center">6.8</td><td align="center">6.5</td><td align="center">5.6</td></tr><tr><td>Change from baseline, %</td><td align="center">–45.7 ± 26.7</td><td align="center">–41.4 ± 15.9</td><td align="center">–48.9 ± 19.7</td><td align="center">–58.1 ± 23.4</td></tr><tr><td>Difference in adjusted means, %<xref rid="tbl3fnc" ref-type="table-fn">c</xref></td><td align="center">—</td><td align="center">1.2 (–20.0 to 22.4)</td><td align="center">–2.3 (–23.1 to 18.5)</td><td align="center">–12.3 (–33.1 to 8.5)</td></tr><tr><td>Tapered to 0 mg and maintained taper</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">3 (33.3)</td></tr></tbody></table><table-wrap-foot><fn><p>Data are presented as No. (%), mean ± SD, mean, or time-adjusted area under the curve (95% CI).</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl3fna"><label>a</label><p id="ntpara0025">Any corticosteroid that was not prednisone was converted to prednisone equivalent dose. All end points use the posttaper period (day 51 to end of dosing).</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl3fnb"><label>b</label><p id="ntpara0030">Adjusted means from analysis of covariance adjusting for baseline steroid use.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl3fnc"><label>c</label><p id="ntpara0035">Time-adjusted area under the curve of percent change from baseline, <italic>P</italic> &gt; .05.</p></fn></table-wrap-foot></table-wrap></p>
                <p id="p0120">Overall, the two highest doses of efzofitimod resulted in improvements in key lung function parameters at week 24 from baseline compared with placebo, consistent with a dose-dependent effect (<xref rid="appsec1" ref-type="sec">e-Table 2</xref>). Relative to placebo, the effects of 5 mg/kg efzofitimod were observed early (eg, week 4 for FVC % predicted and week 12 for D<sc>l<sc>co</sc></sc> % predicted) and were maintained across all evaluated time points through week 24. Overall, FVC % predicted declined over the study period with placebo and 1 mg/kg efzofitimod and increased with the higher doses of efzofitimod (<xref rid="fig2" ref-type="fig">Fig 2</xref>). Although the improvements in FVC % predicted and D<sc>lco</sc> % predicted did not achieve statistical significance at the 5 mg/kg dose level, in part because of the limited sample size, the trend we observed signifies the possibility of biological activity warranting further investigation in a larger population.<fig id="fig2"><label>Figure 2</label><caption><p>A, B, Line graphs showing change from baseline lung function in the efzofitimod vs the placebo groups (modified intention-to-treat population): absolute FVC % predicted (A) and absolute change from baseline in FVC % predicted (B) from day 1 to the end of study.</p></caption><graphic xlink:href="gr2"/></fig></p>
                <p id="p0125">Results observed with the PROs evaluated support the hypothesis that the 5 mg/kg dose group may provide a benefit, with trends that occasionally were statistically significant improvements in the mean change from baseline to week 24 for SAT lung, KSQ lung, KSQ GH, and FAS compared with placebo (<xref rid="tbl4" ref-type="table">Table 4</xref>); trends in PROs appeared before week 24 (<xref rid="appsec1" ref-type="sec">e-Fig 1</xref>). After 5 mg/kg efzofitimod, significant improvements were observed before week 24 as follows: SAT lung, statistical improvement observed by week 12 (<xref rid="appsec1" ref-type="sec">e-Table 3</xref>); KSQ lung, statistical improvement observed by week 8 (<xref rid="appsec1" ref-type="sec">e-Table 4</xref>); KSQ GH, statistical improvement observed by week 4 and maintained through week 24 (<xref rid="appsec1" ref-type="sec">e-Table 5</xref>); and trends toward improvement in FAS observed at week 8 (<xref rid="appsec1" ref-type="sec">e-Table 6</xref>). The changes in other PROs or PRO domains were variable (<xref rid="appsec1" ref-type="sec">e-Table 7</xref>).<table-wrap position="float" id="tbl4"><label>Table 4</label><caption><p>Change in PROs at Week 24 from Baseline in the Efzofitmod vs Placebo Groups (Modified Intention-to-Treat Population)</p></caption><table frame="hsides" rules="groups"><thead><tr><th>PRO Measurement (Adjusted Mean<xref rid="tbl4fna" ref-type="table-fn">a</xref>)</th><th>1 mg/kg (n = 8)</th><th>3 mg/kg (n = 8)</th><th>5 mg/kg (n = 9)</th></tr></thead><tbody><tr><td>SAT lung</td><td/><td/><td/></tr><tr><td> Difference in Least Square Means</td><td align="center">4.67</td><td align="center">–6.66</td><td align="center">–6.42</td></tr><tr><td> 95% CI</td><td align="center">–1.15, 8.19</td><td align="center">–12.22, –0.47</td><td align="center">–11.7, –1.13</td></tr><tr><td> <italic>P</italic> value</td><td align="center">.18</td><td align="center"><bold>.038</bold></td><td align="center"><bold>.018</bold></td></tr><tr><td>KSQ lung</td><td/><td/><td/></tr><tr><td> Difference in Least Square Means</td><td align="center">–6.41</td><td align="center">11.29</td><td align="center">16.17</td></tr><tr><td> 95% CI</td><td align="center">–20.47, 7.65</td><td align="center">–3.39, 25.96</td><td align="center">2.49, 29.85</td></tr><tr><td> <italic>P</italic> value</td><td align="center">.35</td><td align="center">.12</td><td align="center"><bold>.022</bold></td></tr><tr><td>KSQ general health</td><td/><td/><td/></tr><tr><td> Difference in Least Square Means</td><td align="center">–5.1</td><td align="center">2.13</td><td align="center">18.33</td></tr><tr><td> 95% CI</td><td align="center">–18.52, 8.32</td><td align="center">–12.76, 17.01</td><td align="center">5.16, 31.49</td></tr><tr><td> <italic>P</italic> value</td><td align="center">.44</td><td align="center">.77</td><td align="center"><bold>.008</bold></td></tr><tr><td>FAS total</td><td/><td/><td/></tr><tr><td> Difference in Least Square Means</td><td align="center">0.76</td><td align="center">–4.78</td><td align="center">–7.77</td></tr><tr><td> 95% CI</td><td align="center">–5.09, 6.62</td><td align="center">–11.22, 1.65</td><td align="center">–13.50, –2.03</td></tr><tr><td> <italic>P</italic> value</td><td align="center">.79</td><td align="center">.14</td><td align="center"><bold>.010</bold></td></tr></tbody></table><table-wrap-foot><fn><p>Boldfaced values denote significance <italic>P</italic> &lt; .05. FAS = Fatigue Assessment Scale; KSQ = King’s Sarcoidosis Questionnaire; PRO = patient-reported outcome; SAT = Sarcoidosis Assessment Tool.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl4fna"><label>a</label><p id="ntpara0040">Adjusted means taken from mixed model for repeated measures analysis adjusting for corresponding baseline score.</p></fn></table-wrap-foot></table-wrap></p>
              </sec>
            </sec>
            <sec id="sec3">
              <title>Discussion</title>
              <p id="p0130">The results from the present study suggest that efzofitimod is safe and well tolerated in patients with pulmonary sarcoidosis, with no clear dose relationship regarding the incidence of TEAEs. Specifically, no apparent trends overall, within or across efzofitimod treatment groups, were seen regarding change from baseline in clinical laboratory test results, and no notable differences from placebo were observed. No deaths and or discontinuations occurred because of serious AEs in efzofitimod-treated patients. Overall, a low rate of serious or related AEs were noted, with no dose-dependent relationship between AE frequency and increased dose. The nonserious Grade 3 AEs reported after efzofitimod treatment (depression, toothache, and myalgia) were deemed by the investigator to be unlikely to be related to the study drug and did not result in hospitalization or threat of hospitalization. No immunogenicity was reported, as supported by the low incidence of patients with IRRs (n = 1) and the lack of antidrug antibody induction after repeat infusions.</p>
              <p id="p0135">All efzofitimod treatment groups showed a lower corticosteroid use at week 24 compared with the placebo group, which seemed to be dose dependent, with the largest difference observed in the 5 mg/kg treatment group. Four patients were able to taper off prednisone completely (one patient in the placebo group and three patients receiving 5 mg/kg). However, the patient receiving placebo could not be maintained off prednisone for more than 8 weeks because of worsening sarcoidosis and required resumption of prednisone to 10 mg/d. Overall, corticosteroid tapering was possible in all groups, consistent with prior data showing that patients with sarcoidosis in clinical trials can taper corticosteroid successfully over a span of several months.<xref rid="bib25" ref-type="bibr"><sup>26</sup></xref> However, 20% to 74% of patients will experience relapses, with approximately 50% occurring within 6 months of stopping therapy.<xref rid="bib26" ref-type="bibr"><sup>27</sup></xref><sup>,</sup><xref rid="bib27" ref-type="bibr"><sup>28</sup></xref> Despite the short duration of this trial, we were able to demonstrate numerical differences in tolerance to corticosteroid taper among the study groups, which may suggest biological activity of the medication. Although the magnitude of steroid reduction might be deemed small, steroid toxicity depends on cumulative exposure (daily dose × duration). A 10% decrease in the daily dose may result in a meaningful decrease in the cumulative exposure over 1 year. Indeed, the European Repitatory Society (ERS) considers steroid reduction a critical outcome measure.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref></p>
              <p id="p0140">Compared with placebo, the highest doses of efzofitimod resulted in improvements in FVC % predicted and D<sc>lco</sc> % predicted through week 24, suggesting a dose-dependent effect on lung function. The improvement of FVC % predicted observed in the current study was small, but all patients were receiving baseline antiinflammatory therapy for pulmonary sarcoidosis at the time of study entry. Studies of chronic pulmonary sarcoidosis rarely have demonstrated a significant improvement in FVC % predicted.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref><sup>,</sup><xref rid="bib28" ref-type="bibr"><sup>29</sup></xref> The changes in FVC % predicted reported herein were similar to those observed in the treatment arm of a randomized trial of infliximab, in which the mean 24-week improvement was 2.5%.<xref rid="bib29" ref-type="bibr"><sup>30</sup></xref> In that trial, corticosteroids were not tapered. Randomized trials of corticosteroid monotherapy as initial therapy for pulmonary sarcoidosis have found similar improvements in FVC % predicted.<xref rid="bib30" ref-type="bibr"><sup>31</sup></xref><sup>,</sup><xref rid="bib31" ref-type="bibr"><sup>32</sup></xref></p>
              <p id="p0145">Changes in QOL have been considered a major priority for treatment of sarcoidosis.<xref rid="bib33" ref-type="bibr"><sup>33</sup></xref> QOL end points were exploratory assessments that were not corrected for multiple hypothesis testing. We observed significant improvements at week 24 in PROs, such as SAT lung, KSQ lung, KSQ GH, and FAS, in the 5 mg/kg group. Patients who received 5 mg/kg efzofitimod demonstrated significant improvements in KSQ lung at week 8 and significant improvements in KSQ GH as early as week 4; both of these PROs maintained significance through week 24. The magnitude of change in these PROs at 24 weeks exceeded the minimal clinically important differences (MCIDs). For example, placebo-adjusted KSQ GH improved by 18.3 points with 5 mg/kg efzofitimod vs the MCID of 8 points; for KSQ lung, both the 3 mg/kg (+11.3 points) and 5 mg/kg (+16.2 points) efzofitimod groups exceeded the MCID of 4 points, although only the highest dose was statistically significant. For the SAT lung (MCID estimate, –2.7 points), the change in the 3 mg/kg (–6.5 points) and 5 mg/kg (–6.4 points) groups both reflect meaningful improvements.<xref rid="bib32" ref-type="bibr"><sup>21</sup></xref> The changes in the FAS also exceeded the MCID of 4 points<xref rid="bib34" ref-type="bibr"><sup>34</sup></xref>; however, these patients may still have noted some fatigue. The magnitude of these changes exceeds those seen in prior studies evaluating changes in health-related QOL during treatment of pulmonary sarcoidosis.<xref rid="bib35" ref-type="bibr"><sup>35</sup></xref><sup>,</sup><xref rid="bib36" ref-type="bibr"><sup>36</sup></xref></p>
              <p id="p0150">The major limitation of this study is the small sample size, and as such the results will need to be confirmed in a larger study. Operational site difficulties imposed by the COVID-19 pandemic accounted for most of the dropouts. Because of the size, baseline imbalances were present for several of the key end points and the CIs are fairly wide, which limits our ability to draw firm conclusions. However, statistical analyses when adjusted for baseline value demonstrated that the major end points exhibited directionality in favor of a beneficial effect of efzofitimod, suggesting that a larger sample may solidify the findings. We also acknowledge that statistical adjustment for multiple hypothesis testing and power analysis were not performed because of the exploratory nature of the study. Most patients in this study were receiving &gt; 10 mg of prednisone; therefore, further improvement in FVC % predicted was not likely to be demonstrated. However, the current findings suggest a corticosteroid-sparing effect and improved QOL beyond the MCID. Another limitation is the absence of a rigid corticosteroid tapering protocol based on defined thresholds for measurable physiologic indexes or PROs. Variability in corticosteroid tapering aggressiveness may introduce residual bias in the results, but in general this effect likely would tend to reduce the chances of positive findings, rather than increase them, because the patients were randomized. Allowing some investigator discretion about corticosteroid tapering more accurately mirrors usual practice. It is also not possible to determine whether improvements in QOL scores directly reflect efzofitimod activity or occurred indirectly because efzofitimod allowed a greater reduction of prednisone, which has been associated with worse QOL as measured by the Short-Form 36 (SF-36) and St. George’s Respiratory Questionnaire (SGRQ).<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref> The dose response suggests that the medication itself, rather than a corticosteroid reduction, is more likely to contribute to the observed improvement. Finally, several patients dropped out of the study because of the challenges of clinical trials during the COVID-19 pandemic.</p>
            </sec>
            <sec id="sec4">
              <title>Interpretation</title>
              <p id="p0155">In patients with pulmonary sarcoidosis, efzofitimod was safe and well tolerated. Exploratory analyses suggest clinically meaningful improvements after 5 mg/kg efzofitimod with corticosteroid use and improvements in lung function and PROs compared with placebo, without increasing the risk of side effects. However, because of the limited number of patients enrolled in this trial, these findings should be considered only as hypothesis generating. These results support further evaluation in prospective trials of efzofitimod in patients with pulmonary sarcoidosis.</p>
            </sec>
            <sec id="sec5">
              <title>Funding/Support</title>
              <p id="p0165">Supported by <funding-source id="gs1"><institution-wrap><institution-id institution-id-type="doi">10.13039/100014933</institution-id><institution>aTyr Pharma</institution></institution-wrap></funding-source> L. A. M. is supported by the <funding-source id="gs2"><institution-wrap><institution-id institution-id-type="doi">10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source> [Grants R01HL140357, R01HL142049, and R01HL136681]. P. H. S. S. is supported by the <funding-source id="gs3"><institution-wrap><institution-id institution-id-type="doi">10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source> [Grants R13HL142300and R01HL131745] and the <funding-source id="gs4">American Thoracic Society Foundation</funding-source>.</p>
            </sec>
            <sec id="sec6">
              <title>Financial/Nonfinancial Disclosures</title>
              <p id="p0170">The authors have reported to <italic>CHEST</italic> the following: D. A. C. has received grants from <funding-source id="gs5"><institution-wrap><institution-id institution-id-type="doi">10.13039/100014468</institution-id><institution>Mallinckrodt Pharmaceuticals</institution></institution-wrap></funding-source>, <funding-source id="gs6">Boehringer Ingelheim</funding-source>, the <funding-source id="gs7"><institution-wrap><institution-id institution-id-type="doi">10.13039/100015131</institution-id><institution>Foundation for Sarcoidosis Research</institution></institution-wrap></funding-source> (FSR), and the <funding-source id="gs8">Ann Theodore Foundation</funding-source>; serves as a consultant for Roivant Sciences and Boehringer Ingelheim; serves as a member of the adjudication committee for Pliant Therapeutics; and serves as president of the World Association for Sarcoidosis and Other Granulomatous Disorders. S. A. received conference travel support from and is an advisory board member for aTyr Pharma, Inc. C. C. W. H. has received grant funding from Mallinckrodt Pharmaceuticals. L. A. M. has received grants from the FSR, Mallinckrodt Pharmaceuticals, and the University of Cincinnati (Mallinckrodt Pharmaceuticals Foundation Grant) and serves on the scientific advisory board for FSR and the global advisory board for aTyr Pharma, Inc. O. N. O. has received travel support from aTyr Pharma, Inc., was provided equipment for conducting the current study, and serves on the scientific advisory board for FSR. P. H. S. S. has received grants the FSR, aTyr Pharma, Inc., and Novartis. S. S. and G. W. are employed by and own stock in aTyr Pharma, Inc. N. K. has received payments from aTyr Pharma, Inc., for consultancy on the statistical analysis and interpretation of data, payments from Savara Pharmaceuticals for consultancy on the design and analysis of clinical trials in respiratory diseases, and previously held stock in Roche. R. B. has received grants from <funding-source id="gs9"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004326</institution-id><institution>Bayer</institution></institution-wrap></funding-source>, <funding-source id="gs10"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004328</institution-id><institution>Genentech</institution></institution-wrap></funding-source>, Mallinckrodt Pharmaceuticals, the FSR, and <funding-source id="gs11">Actelion</funding-source>; consulting fees from Mallinckrodt Pharmaceuticals, Meitheal Pharmaceuticals, Actelion, and Kinevant; and payment for speaker bureaus from Mallinckrodt Pharmaceuticals, United Therapeutics, and Boehringer Ingelheim. None declared (J. B., W. E. J., L. T. M., and N. J. S.).</p>
            </sec>
          </body>
          <back>
            <ref-list id="cebib0010">
              <title>References</title>
              <ref id="bib1">
                <label>1</label>
                <element-citation publication-type="journal" id="sref1">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Culver</surname>
                      <given-names>D.A.</given-names>
                    </name>
                    <name>
                      <surname>Judson</surname>
                      <given-names>M.A.</given-names>
                    </name>
                  </person-group>
                  <article-title>New advances in the management of pulmonary sarcoidosis</article-title>
                  <source>BMJ</source>
                  <volume>367</volume>
                  <year>2019</year>
                  <fpage>l5553</fpage>
                  <pub-id pub-id-type="pmid">31641045</pub-id>
                </element-citation>
              </ref>
              <ref id="bib2">
                <label>2</label>
                <element-citation publication-type="journal" id="sref2">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Baughman</surname>
                      <given-names>R.P.</given-names>
                    </name>
                    <name>
                      <surname>Valeyre</surname>
                      <given-names>D.</given-names>
                    </name>
                    <name>
                      <surname>Korsten</surname>
                      <given-names>P.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>ERS clinical practice guidelines on treatment of sarcoidosis</article-title>
                  <source>Eur Respir J</source>
                  <volume>58</volume>
                  <issue>6</issue>
                  <year>2021</year>
                  <object-id pub-id-type="publisher-id">20040709</object-id>
                </element-citation>
              </ref>
              <ref id="bib3">
                <label>3</label>
                <element-citation publication-type="journal" id="sref3">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Drent</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Costabel</surname>
                      <given-names>U.</given-names>
                    </name>
                    <name>
                      <surname>Crouser</surname>
                      <given-names>E.D.</given-names>
                    </name>
                    <name>
                      <surname>Grunewald</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Bonella</surname>
                      <given-names>F.</given-names>
                    </name>
                  </person-group>
                  <article-title>Misconceptions regarding symptoms of sarcoidosis</article-title>
                  <source>Lancet Respir Med</source>
                  <volume>9</volume>
                  <issue>8</issue>
                  <year>2021</year>
                  <fpage>816</fpage>
                  <lpage>818</lpage>
                  <pub-id pub-id-type="pmid">34216548</pub-id>
                </element-citation>
              </ref>
              <ref id="bib4">
                <label>4</label>
                <element-citation publication-type="journal" id="sref4">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Faverio</surname>
                      <given-names>P.</given-names>
                    </name>
                    <name>
                      <surname>De Giacomi</surname>
                      <given-names>F.</given-names>
                    </name>
                    <name>
                      <surname>Bonaiti</surname>
                      <given-names>G.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Management of chronic respiratory failure in interstitial lung diseases: overview and clinical insights</article-title>
                  <source>Int J Med</source>
                  <volume>16</volume>
                  <issue>7</issue>
                  <year>2019</year>
                  <fpage>967</fpage>
                  <lpage>980</lpage>
                </element-citation>
              </ref>
              <ref id="bib5">
                <label>5</label>
                <element-citation publication-type="journal" id="sref5">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Schutt</surname>
                      <given-names>A.C.</given-names>
                    </name>
                    <name>
                      <surname>Bullington</surname>
                      <given-names>W.M.</given-names>
                    </name>
                    <name>
                      <surname>Judson</surname>
                      <given-names>M.A.</given-names>
                    </name>
                  </person-group>
                  <article-title>Pharmacotherapy for pulmonary sarcoidosis: a Delphi consensus study</article-title>
                  <source>Respir Med</source>
                  <volume>104</volume>
                  <issue>5</issue>
                  <year>2010</year>
                  <fpage>717</fpage>
                  <lpage>723</lpage>
                  <pub-id pub-id-type="pmid">20089389</pub-id>
                </element-citation>
              </ref>
              <ref id="bib6">
                <label>6</label>
                <element-citation publication-type="journal" id="sref6">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Khan</surname>
                      <given-names>N.A.</given-names>
                    </name>
                    <name>
                      <surname>Donatelli</surname>
                      <given-names>C.V.</given-names>
                    </name>
                    <name>
                      <surname>Tonelli</surname>
                      <given-names>A.R.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Toxicity risk from glucocorticoids in sarcoidosis patients</article-title>
                  <source>Respir Med</source>
                  <volume>132</volume>
                  <year>2017</year>
                  <fpage>9</fpage>
                  <lpage>14</lpage>
                  <pub-id pub-id-type="pmid">29229111</pub-id>
                </element-citation>
              </ref>
              <ref id="bib7">
                <label>7</label>
                <element-citation publication-type="journal" id="sref7">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cox</surname>
                      <given-names>S.E.</given-names>
                    </name>
                    <name>
                      <surname>Donohue</surname>
                      <given-names>J.F.</given-names>
                    </name>
                    <name>
                      <surname>Brown</surname>
                      <given-names>C.D.</given-names>
                    </name>
                    <name>
                      <surname>Kataria</surname>
                      <given-names>Y.P.</given-names>
                    </name>
                    <name>
                      <surname>Judson</surname>
                      <given-names>M.A.</given-names>
                    </name>
                  </person-group>
                  <article-title>Health-related quality of life in persons with sarcoidosis</article-title>
                  <source>Chest</source>
                  <volume>125</volume>
                  <issue>3</issue>
                  <year>2004</year>
                  <fpage>997</fpage>
                  <lpage>1004</lpage>
                  <pub-id pub-id-type="pmid">15006960</pub-id>
                </element-citation>
              </ref>
              <ref id="bib8">
                <label>8</label>
                <element-citation publication-type="journal" id="sref8">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Judson</surname>
                      <given-names>M.A.</given-names>
                    </name>
                  </person-group>
                  <article-title>The treatment of pulmonary sarcoidosis</article-title>
                  <source>Respir Med</source>
                  <volume>106</volume>
                  <issue>10</issue>
                  <year>2012</year>
                  <fpage>1351</fpage>
                  <lpage>1361</lpage>
                  <pub-id pub-id-type="pmid">22495110</pub-id>
                </element-citation>
              </ref>
              <ref id="bib9">
                <label>9</label>
                <element-citation publication-type="journal" id="sref9">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Zhou</surname>
                      <given-names>J.J.</given-names>
                    </name>
                    <name>
                      <surname>Wang</surname>
                      <given-names>F.</given-names>
                    </name>
                    <name>
                      <surname>Xu</surname>
                      <given-names>Z.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Secreted histidyl-tRNA synthetase splice variants elaborate major epitopes for autoantibodies in inflammatory myositis</article-title>
                  <source>J Biol Chem</source>
                  <volume>289</volume>
                  <issue>28</issue>
                  <year>2014</year>
                  <fpage>19269</fpage>
                  <lpage>19275</lpage>
                  <pub-id pub-id-type="pmid">24898250</pub-id>
                </element-citation>
              </ref>
              <ref id="bib10">
                <label>10</label>
                <element-citation publication-type="journal" id="sref0">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lo</surname>
                      <given-names>W.S.</given-names>
                    </name>
                    <name>
                      <surname>Gardiner</surname>
                      <given-names>E.</given-names>
                    </name>
                    <name>
                      <surname>Xu</surname>
                      <given-names>Z.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Human tRNA synthetase catalytic nulls with diverse functions</article-title>
                  <source>Science</source>
                  <volume>345</volume>
                  <issue>6194</issue>
                  <year>2014</year>
                  <fpage>328</fpage>
                  <lpage>332</lpage>
                  <pub-id pub-id-type="pmid">25035493</pub-id>
                </element-citation>
              </ref>
              <ref id="bib11">
                <label>11</label>
                <element-citation publication-type="journal" id="sref11">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Xu</surname>
                      <given-names>Z.</given-names>
                    </name>
                    <name>
                      <surname>Chong</surname>
                      <given-names>Y.</given-names>
                    </name>
                    <name>
                      <surname>Crampton</surname>
                      <given-names>S.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>ATYR1923 specifically binds to neuropilin-2, a novel therapeutic target for the treatment of immune-mediated diseases [abstract]</article-title>
                  <source>Am J Respir Crit Care Med</source>
                  <volume>201</volume>
                  <year>2020</year>
                  <fpage>A3074</fpage>
                </element-citation>
              </ref>
              <ref id="bib12">
                <label>12</label>
                <element-citation publication-type="journal" id="sref12">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Immormino</surname>
                      <given-names>R.M.</given-names>
                    </name>
                    <name>
                      <surname>Lauzier</surname>
                      <given-names>D.C.</given-names>
                    </name>
                    <name>
                      <surname>Nakano</surname>
                      <given-names>H.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Neuropilin-2 regulates airway inflammatory responses to inhaled lipopolysaccharide</article-title>
                  <source>Am J Physiol Lung Cell Mol Physiol</source>
                  <volume>315</volume>
                  <issue>2</issue>
                  <year>2018</year>
                  <fpage>L202</fpage>
                  <lpage>L211</lpage>
                  <pub-id pub-id-type="pmid">29671604</pub-id>
                </element-citation>
              </ref>
              <ref id="bib13">
                <label>13</label>
                <element-citation publication-type="journal" id="sref13">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Paz</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Chu</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Ferrer</surname>
                      <given-names>M.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Neuropilin-2, the specific binding partner to ATYR1923, is expressed in sarcoid granulomas and key immune cells [abstract]</article-title>
                  <source>Am J Respir Crit Care Med</source>
                  <volume>201</volume>
                  <year>2020</year>
                  <fpage>A3099</fpage>
                </element-citation>
              </ref>
              <ref id="bib14">
                <label>14</label>
                <element-citation publication-type="journal" id="sref14">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Burkett</surname>
                      <given-names>C.</given-names>
                    </name>
                    <name>
                      <surname>Seikkula</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Eide</surname>
                      <given-names>L.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>ATYR1923 modulates the inflammatory response in experimental models of interstitial lung disease [abstract]</article-title>
                  <source>Am J Respir Crit Care Med</source>
                  <volume>199</volume>
                  <year>2019</year>
                  <fpage>A2421</fpage>
                </element-citation>
              </ref>
              <ref id="bib15">
                <label>15</label>
                <element-citation publication-type="journal" id="sref15">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Adams</surname>
                      <given-names>R.A.</given-names>
                    </name>
                    <name>
                      <surname>Fernandes-Cerqueira</surname>
                      <given-names>C.</given-names>
                    </name>
                    <name>
                      <surname>Notarnicola</surname>
                      <given-names>A.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Serum-circulating his-tRNA synthetase inhibits organ-targeted immune responses</article-title>
                  <source>Cell Mol Immunol</source>
                  <volume>18</volume>
                  <issue>6</issue>
                  <year>2021</year>
                  <fpage>1463</fpage>
                  <lpage>1475</lpage>
                  <pub-id pub-id-type="pmid">31797905</pub-id>
                </element-citation>
              </ref>
              <ref id="bib16">
                <label>16</label>
                <element-citation publication-type="journal" id="sref16">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Paz</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Polizzi</surname>
                      <given-names>C.</given-names>
                    </name>
                    <name>
                      <surname>Chu</surname>
                      <given-names>D.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>ATYR1923 reduces neutrophil Infiltration in an acute lipopolysaccharide (LPS) lung injury model</article-title>
                  <comment>[abstract]</comment>
                  <source>Keystone Symposia Conference</source>
                  <volume>B7</volume>
                  <year>2019</year>
                </element-citation>
              </ref>
              <ref id="bib17">
                <label>17</label>
                <element-citation publication-type="journal" id="sref17">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Nangle</surname>
                      <given-names>L.A.</given-names>
                    </name>
                    <name>
                      <surname>Tong</surname>
                      <given-names>Y.</given-names>
                    </name>
                    <name>
                      <surname>Crampton</surname>
                      <given-names>S.P.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>The resokine pathway is implicated in the pathology of interstitial lung disease [abstract]</article-title>
                  <source>Am J Respir Crit Care Med</source>
                  <volume>195</volume>
                  <year>2017</year>
                  <fpage>A7068</fpage>
                </element-citation>
              </ref>
              <ref id="bib18">
                <label>18</label>
                <element-citation publication-type="journal" id="sref18">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ogilvie</surname>
                      <given-names>K.</given-names>
                    </name>
                    <name>
                      <surname>Xu</surname>
                      <given-names>Q.</given-names>
                    </name>
                    <name>
                      <surname>Do</surname>
                      <given-names>M.H.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Pre-clinical characterization of iMod. Fc, an immune-modulatory therapeutic with potentially broad application in interstitial lung diseases</article-title>
                  <comment>[abstract]</comment>
                  <source>Am J Respir Crit Care Med</source>
                  <volume>197</volume>
                  <year>2018</year>
                  <fpage>A1064</fpage>
                </element-citation>
              </ref>
              <ref id="bib19">
                <label>19</label>
                <element-citation publication-type="other" id="sref19">
                  <person-group person-group-type="author">
                    <collab>aTyr Pharma, Inc.</collab>
                  </person-group>
                  <article-title>aTyr Pharma announces positive phase 1 data for ATYR1923 therapeutic candidate [online press release]. June 26, 2018. aTyr Pharma, Inc.</article-title>
                  <comment>website</comment>
                  <ext-link ext-link-type="uri" xlink:href="https://investors.atyrpharma.com/news-releases/news-release-details/atyr-pharma-announces-positive-phase-1-data-atyr1923-therapeutic" id="intref0025">https://investors.atyrpharma.com/news-releases/news-release-details/atyr-pharma-announces-positive-phase-1-data-atyr1923-therapeutic</ext-link>
                </element-citation>
              </ref>
              <ref id="bib20">
                <label>20</label>
                <element-citation publication-type="journal" id="sref20">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hunninghake</surname>
                      <given-names>G.W.</given-names>
                    </name>
                    <name>
                      <surname>Costabel</surname>
                      <given-names>U.</given-names>
                    </name>
                    <name>
                      <surname>Ando</surname>
                      <given-names>M.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders</article-title>
                  <source>Sarcoidosis Vasc Diffuse Lung Dis</source>
                  <volume>16</volume>
                  <issue>2</issue>
                  <year>1999</year>
                  <fpage>149</fpage>
                  <lpage>173</lpage>
                  <pub-id pub-id-type="pmid">10560120</pub-id>
                </element-citation>
              </ref>
              <ref id="bib32">
                <label>21</label>
                <element-citation publication-type="journal" id="sref32">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Judson</surname>
                      <given-names>M.A.</given-names>
                    </name>
                    <name>
                      <surname>Mack</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Beaumont</surname>
                      <given-names>J.L.</given-names>
                    </name>
                    <name>
                      <surname>Watt</surname>
                      <given-names>R.</given-names>
                    </name>
                    <name>
                      <surname>Barnathan</surname>
                      <given-names>E.S.</given-names>
                    </name>
                    <name>
                      <surname>Victorson</surname>
                      <given-names>D.E.</given-names>
                    </name>
                  </person-group>
                  <article-title>Validation and important differences for the Sarcoidosis Assessment Tool. A new patient-reported outcome measure</article-title>
                  <source>Am J Respir Crit Care Med</source>
                  <volume>191</volume>
                  <issue>7</issue>
                  <year>2015</year>
                  <fpage>786</fpage>
                  <lpage>795</lpage>
                  <pub-id pub-id-type="pmid">25594886</pub-id>
                </element-citation>
              </ref>
              <ref id="bib21">
                <label>22</label>
                <element-citation publication-type="journal" id="sref21">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Patel</surname>
                      <given-names>A.S.</given-names>
                    </name>
                    <name>
                      <surname>Siegert</surname>
                      <given-names>R.J.</given-names>
                    </name>
                    <name>
                      <surname>Creamer</surname>
                      <given-names>D.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>The development and validation of the King’s Sarcoidosis Questionnaire for the assessment of health status</article-title>
                  <source>Thorax</source>
                  <volume>68</volume>
                  <issue>1</issue>
                  <year>2013</year>
                  <fpage>57</fpage>
                  <lpage>65</lpage>
                  <pub-id pub-id-type="pmid">23065052</pub-id>
                </element-citation>
              </ref>
              <ref id="bib22">
                <label>23</label>
                <element-citation publication-type="journal" id="sref22">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Birring</surname>
                      <given-names>S.S.</given-names>
                    </name>
                    <name>
                      <surname>Prudon</surname>
                      <given-names>B.</given-names>
                    </name>
                    <name>
                      <surname>Carr</surname>
                      <given-names>A.J.</given-names>
                    </name>
                    <name>
                      <surname>Singh</surname>
                      <given-names>S.J.</given-names>
                    </name>
                    <name>
                      <surname>Morgan</surname>
                      <given-names>M.D.L.</given-names>
                    </name>
                    <name>
                      <surname>Pavord</surname>
                      <given-names>I.D.</given-names>
                    </name>
                  </person-group>
                  <article-title>Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ)</article-title>
                  <source>Thorax</source>
                  <volume>58</volume>
                  <issue>4</issue>
                  <year>2003</year>
                  <fpage>339</fpage>
                  <lpage>343</lpage>
                  <pub-id pub-id-type="pmid">12668799</pub-id>
                </element-citation>
              </ref>
              <ref id="bib23">
                <label>24</label>
                <element-citation publication-type="journal" id="sref23">
                  <person-group person-group-type="author">
                    <name>
                      <surname>De Vries</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Michielsen</surname>
                      <given-names>H.</given-names>
                    </name>
                    <name>
                      <surname>Van Heck</surname>
                      <given-names>G.L.</given-names>
                    </name>
                    <name>
                      <surname>Drent</surname>
                      <given-names>M.</given-names>
                    </name>
                  </person-group>
                  <article-title>Measuring fatigue in sarcoidosis: the Fatigue Assessment Scale (FAS)</article-title>
                  <source>Br J Health Psychol</source>
                  <volume>9</volume>
                  <issue>3</issue>
                  <year>2004</year>
                  <fpage>279</fpage>
                  <lpage>291</lpage>
                  <pub-id pub-id-type="pmid">15296678</pub-id>
                </element-citation>
              </ref>
              <ref id="bib24">
                <label>25</label>
                <element-citation publication-type="journal" id="sref24">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Witek</surname>
                      <given-names>T.</given-names>
                    </name>
                    <name>
                      <surname>Mahler</surname>
                      <given-names>D.</given-names>
                    </name>
                  </person-group>
                  <article-title>Minimal important difference of the transition dyspnoea index in a multinational clinical trial</article-title>
                  <source>Eur Respir J</source>
                  <volume>21</volume>
                  <issue>2</issue>
                  <year>2003</year>
                  <fpage>267</fpage>
                  <lpage>272</lpage>
                  <pub-id pub-id-type="pmid">12608440</pub-id>
                </element-citation>
              </ref>
              <ref id="bib25">
                <label>26</label>
                <element-citation publication-type="journal" id="sref25">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Judson</surname>
                      <given-names>M.A.</given-names>
                    </name>
                    <name>
                      <surname>Baughman</surname>
                      <given-names>R.P.</given-names>
                    </name>
                    <name>
                      <surname>Costabel</surname>
                      <given-names>U.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis</article-title>
                  <source>Eur Respir J</source>
                  <volume>44</volume>
                  <issue>5</issue>
                  <year>2014</year>
                  <fpage>1296</fpage>
                  <lpage>1307</lpage>
                  <pub-id pub-id-type="pmid">25034562</pub-id>
                </element-citation>
              </ref>
              <ref id="bib26">
                <label>27</label>
                <element-citation publication-type="journal" id="sref26">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gottlieb</surname>
                      <given-names>J.E.</given-names>
                    </name>
                    <name>
                      <surname>Israel</surname>
                      <given-names>H.L.</given-names>
                    </name>
                    <name>
                      <surname>Steiner</surname>
                      <given-names>R.M.</given-names>
                    </name>
                    <name>
                      <surname>Triolo</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Patrick</surname>
                      <given-names>H.</given-names>
                    </name>
                  </person-group>
                  <article-title>Outcome in sarcoidosis: the relationship of relapse to corticosteroid therapy</article-title>
                  <source>Chest</source>
                  <volume>111</volume>
                  <issue>3</issue>
                  <year>1997</year>
                  <fpage>623</fpage>
                  <lpage>631</lpage>
                  <pub-id pub-id-type="pmid">9118698</pub-id>
                </element-citation>
              </ref>
              <ref id="bib27">
                <label>28</label>
                <element-citation publication-type="journal" id="sref27">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Rizzato</surname>
                      <given-names>G.</given-names>
                    </name>
                    <name>
                      <surname>Montemurro</surname>
                      <given-names>L.</given-names>
                    </name>
                    <name>
                      <surname>Colombo</surname>
                      <given-names>P.</given-names>
                    </name>
                  </person-group>
                  <article-title>The late follow-up of chronic sarcoid patients previously treated with corticosteroids</article-title>
                  <source>Sarcoidosis Vasc Diffuse Lung Dis</source>
                  <volume>15</volume>
                  <issue>1</issue>
                  <year>1998</year>
                  <fpage>52</fpage>
                  <lpage>58</lpage>
                  <pub-id pub-id-type="pmid">9572002</pub-id>
                </element-citation>
              </ref>
              <ref id="bib28">
                <label>29</label>
                <element-citation publication-type="journal" id="sref28">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Baughman</surname>
                      <given-names>R.P.</given-names>
                    </name>
                    <name>
                      <surname>Nunes</surname>
                      <given-names>H.</given-names>
                    </name>
                    <name>
                      <surname>Sweiss</surname>
                      <given-names>N.J.</given-names>
                    </name>
                    <name>
                      <surname>Lower</surname>
                      <given-names>E.E.</given-names>
                    </name>
                  </person-group>
                  <article-title>Established and experimental medical therapy of pulmonary sarcoidosis</article-title>
                  <source>Eur Respir J</source>
                  <volume>41</volume>
                  <year>2013</year>
                  <fpage>1424</fpage>
                  <lpage>1438</lpage>
                  <pub-id pub-id-type="pmid">23397302</pub-id>
                </element-citation>
              </ref>
              <ref id="bib29">
                <label>30</label>
                <element-citation publication-type="journal" id="sref29">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Baughman</surname>
                      <given-names>R.P.</given-names>
                    </name>
                    <name>
                      <surname>Drent</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Kavuru</surname>
                      <given-names>M.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement</article-title>
                  <source>Am J Respir Crit Care Med</source>
                  <volume>174</volume>
                  <issue>7</issue>
                  <year>2006</year>
                  <fpage>795</fpage>
                  <lpage>802</lpage>
                  <pub-id pub-id-type="pmid">16840744</pub-id>
                </element-citation>
              </ref>
              <ref id="bib30">
                <label>31</label>
                <element-citation publication-type="journal" id="sref30">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gibson</surname>
                      <given-names>G.J.</given-names>
                    </name>
                    <name>
                      <surname>Prescott</surname>
                      <given-names>R.J.</given-names>
                    </name>
                    <name>
                      <surname>Muers</surname>
                      <given-names>M.F.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>British Thoracic Society sarcoidosis study: effects of long-term corticosteroid treatment</article-title>
                  <source>Thorax</source>
                  <volume>51</volume>
                  <issue>3</issue>
                  <year>1996</year>
                  <fpage>238</fpage>
                  <lpage>247</lpage>
                  <pub-id pub-id-type="pmid">8779124</pub-id>
                </element-citation>
              </ref>
              <ref id="bib31">
                <label>32</label>
                <element-citation publication-type="journal" id="sref31">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Pietinalho</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Tukiainen</surname>
                      <given-names>P.</given-names>
                    </name>
                    <name>
                      <surname>Haahtela</surname>
                      <given-names>T.</given-names>
                    </name>
                    <name>
                      <surname>Persson</surname>
                      <given-names>T.</given-names>
                    </name>
                    <name>
                      <surname>Selroos</surname>
                      <given-names>O.</given-names>
                    </name>
                    <collab>Finnish Pulmonary Sarcoidosis Study Group</collab>
                  </person-group>
                  <article-title>Early treatment of stage II sarcoidosis improves 5-year pulmonary function</article-title>
                  <source>Chest</source>
                  <volume>121</volume>
                  <issue>1</issue>
                  <year>2002</year>
                  <fpage>24</fpage>
                  <lpage>31</lpage>
                  <pub-id pub-id-type="pmid">11796428</pub-id>
                </element-citation>
              </ref>
              <ref id="bib33">
                <label>33</label>
                <element-citation publication-type="journal" id="sref33">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Baughman</surname>
                      <given-names>R.P.</given-names>
                    </name>
                    <name>
                      <surname>Barriuso</surname>
                      <given-names>R.</given-names>
                    </name>
                    <name>
                      <surname>Beyer</surname>
                      <given-names>K.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Sarcoidosis: patient treatment priorities</article-title>
                  <source>ERJ Open Res</source>
                  <volume>4</volume>
                  <issue>4</issue>
                  <year>2018</year>
                  <fpage>141</fpage>
                  <lpage>143</lpage>
                </element-citation>
              </ref>
              <ref id="bib34">
                <label>34</label>
                <element-citation publication-type="journal" id="sref34">
                  <person-group person-group-type="author">
                    <name>
                      <surname>de Kleijn</surname>
                      <given-names>W.P.E.</given-names>
                    </name>
                    <name>
                      <surname>De Vries</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Wijnen</surname>
                      <given-names>P.A.</given-names>
                    </name>
                    <name>
                      <surname>Drent</surname>
                      <given-names>M.</given-names>
                    </name>
                  </person-group>
                  <article-title>Minimal (clinically) important differences for the Fatigue Assessment Scale in sarcoidosis</article-title>
                  <source>Respir Med</source>
                  <volume>105</volume>
                  <issue>9</issue>
                  <year>2001</year>
                  <fpage>1388</fpage>
                  <lpage>1395</lpage>
                </element-citation>
              </ref>
              <ref id="bib35">
                <label>35</label>
                <element-citation publication-type="journal" id="sref35">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Baughman</surname>
                      <given-names>R.P.</given-names>
                    </name>
                    <name>
                      <surname>Judson</surname>
                      <given-names>M.A.</given-names>
                    </name>
                    <name>
                      <surname>Culver</surname>
                      <given-names>D.A.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Roflumilast (Daliresp®) to reduce acute pulmonary events in fibrotic sarcoidosis: a multi-center, double blind, placebo controlled, randomized clinical trial</article-title>
                  <source>Sarcoidosis Vasc Diffuse Lung Dis</source>
                  <volume>38</volume>
                  <issue>3</issue>
                  <year>2021</year>
                  <object-id pub-id-type="publisher-id">e2021035</object-id>
                </element-citation>
              </ref>
              <ref id="bib36">
                <label>36</label>
                <element-citation publication-type="journal" id="sref36">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Baughman</surname>
                      <given-names>R.P.</given-names>
                    </name>
                    <name>
                      <surname>Sweiss</surname>
                      <given-names>N.</given-names>
                    </name>
                    <name>
                      <surname>Keijsers</surname>
                      <given-names>R.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Repository corticotropin for chronic pulmonary sarcoidosis</article-title>
                  <source>Lung</source>
                  <volume>195</volume>
                  <issue>3</issue>
                  <year>2017</year>
                  <fpage>313</fpage>
                  <lpage>322</lpage>
                  <pub-id pub-id-type="pmid">28353116</pub-id>
                </element-citation>
              </ref>
            </ref-list>
            <sec id="appsec1" sec-type="supplementary-material">
              <title>Supplementary Data</title>
              <p id="p0185">
                <supplementary-material content-type="local-data" id="mmc1">
                  <caption>
                    <title>e-Online Data</title>
                  </caption>
                  <media xlink:href="mmc1.docx"/>
                </supplementary-material>
              </p>
            </sec>
            <ack id="ack0010">
              <title>Acknowledgments</title>
              <p id="p0160"><bold>Author</bold><bold>c</bold><bold>ontributions</bold>: D. A. C., S. S., N. K., G.W., and R. B. contributed to the conception and design of the study. D. A. C., S. A., J. B., C. C. W. H., W. E. J., L. A. M., L. T. M., O. N. O., P. H. S. S., N. J. S., and R. B contributed to acquisition of the data. N. K., S. S., and G. W. vouch for the accuracy and completeness of the data, the statistical analysis, and the fidelity of the study to the protocol. D. A. C., S. S., N. K., G. W., and R. B. drafted and revised the manuscript. All authors reviewed, revised, and approved the manuscript before submission.</p>
              <p id="p0175"><bold>Other contributions:</bold> The authors thank the patients and their families for participating in this study and the Foundation for Sarcoidosis Research for their partnership. Additional writing support was provided by Samantha E. Yohn and graphic design support was provided by John Welle, of Acumen Medical Communications. Additional clinical science support was provided by Vis Niranjan and Abhijeeth Chandrasekaran of RxMD. The Fatigue Assessment Scale was used with permission from the ild care foundation (<ext-link ext-link-type="uri" xlink:href="http://www.ildcare.nl" id="intref0020">www.ildcare.nl</ext-link>).</p>
              <p id="p0180"><bold>Additional information:</bold> The <xref rid="appsec1" ref-type="sec">e-Appendix</xref>, <xref rid="appsec1" ref-type="sec">e-Figure</xref>, and <xref rid="appsec1" ref-type="sec">e-Tables</xref> are available online under “<xref rid="appsec1" ref-type="sec">Supplementary Data</xref>.”</p>
            </ack>
            <fn-group>
              <fn id="d35e922">
                <p id="ntpara0010">This article was presented at the World Association of Sarcoidosis and Other Granulomatous Disorders Virtual Meeting, December 8, 2021; the American Thoracic Society Meeting, May 2022 (P559), San Francisco, CA; and the 28th tRNA Conference, July 16, 2022.</p>
              </fn>
            </fn-group>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
